1. Company is one of the leading companies in hematopoietic stem cell research in China. It has a research and development team composed of Dr. Haigui and senior researchers, and is committed to developing innovative treatment methods and products.
2. As of March 6, 2023, the company has obtained many international patents and won many honors. Stecz-B independently developed by the company is the first internationally approved new drug to support the treatment of myelodysplastic syndrome (MDS) after hematopoietic stem cell transplantation.
3. Fujian Sany Hematopoietic Technology Co., Ltd. also actively promotes the international development of high-end medical technology and has certain influence in overseas markets. The company also pays attention to corporate social responsibility, often participates in charity activities and community building, and makes positive contributions to social development. Fujian Sany Hematopoietic Technology Co., Ltd. is a biomedical enterprise, mainly engaged in the research, development and application of hematopoietic stem cells. The company was established in 20 10 with a registered capital of about 654.38+32 million yuan, and its headquarters is located in Fuzhou, Fujian.